Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Arvinas is a clinical-stage biotechnology company pioneering protein degradation therapeutics using its proprietary PROTAC (PROteolysis TArgeting Chimera) platform. The company's lead programs target androgen receptor (ARV-110) for prostate cancer and estrogen receptor (ARV-471) for breast cancer, with multiple Phase 2/3 trials ongoing. The stock trades on clinical trial readouts, regulatory milestones, and partnership announcements rather than current profitability.
Arvinas monetizes through upfront payments, research funding, and milestone payments from pharmaceutical partners who license its PROTAC platform for specific targets. The company retains rights to its wholly-owned oncology programs (ARV-110, ARV-471) which could generate product revenue post-approval. Long-term value creation depends on clinical success leading to either product commercialization or acquisition by larger pharma. Pricing power will be determined by clinical differentiation versus existing therapies in crowded oncology markets.
ARV-471 (breast cancer) Phase 3 trial enrollment updates and interim efficacy data - primary near-term catalyst
ARV-110 (prostate cancer) Phase 2 expansion data and potential Phase 3 initiation decisions
New partnership announcements or expansion of existing collaborations (Pfizer, Bayer, Genentech)
FDA regulatory interactions, breakthrough therapy designations, or accelerated approval pathway eligibility
Cash runway updates and financing events - critical given negative $300M annual cash burn
Clinical trial failure risk - ARV-471 or ARV-110 missing efficacy/safety endpoints would eliminate 70%+ of company value given pipeline concentration
Regulatory approval uncertainty - FDA may require additional trials or reject applications even with positive Phase 3 data, extending timeline 2-3 years
Competitive protein degradation platforms from Nurix, Kymera, C4 Therapeutics targeting similar mechanisms and indications
Patent expiration risk on core PROTAC technology (estimated 2030s) could erode competitive moat before commercialization
Established oncology therapies in prostate cancer (Xtandi, Zytiga, Erleada) and breast cancer (Ibrance, Verzenio) with proven efficacy create high bar for differentiation
Large pharma internal protein degradation programs (Roche, Bristol Myers Squibb) could bypass need for Arvinas partnerships
Next-generation ADCs and bispecifics targeting same patient populations may offer superior efficacy profiles
Cash burn of approximately $300M annually with $0.8B market cap creates dilution risk - likely needs financing within 12-18 months based on operating cash flow
Negative operating cash flow of $300M limits financial flexibility to expand pipeline or in-license complementary assets
Low market cap relative to development costs increases vulnerability to hostile acquisition or unfavorable partnership terms
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact: (1) ability to raise capital at attractive valuations, (2) pharmaceutical partner willingness to fund collaborations, and (3) M&A appetite from potential acquirers. Biotech sector historically shows modest correlation to broader economic cycles.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (product revenues not expected until 2027+). Higher rates also increase cost of capital for future financings and reduce investor appetite for unprofitable growth stocks. With 5.70x current ratio and minimal debt (0.02 D/E), immediate financing cost impact is negligible, but future dilution risk increases in high-rate environments.
minimal - Company maintains strong liquidity position with current ratio of 5.70 and negligible debt. Credit market conditions affect ability to access convertible debt markets (common biotech financing tool) but company primarily relies on equity financing and partnership payments rather than traditional credit facilities.
growth - High-risk, high-reward clinical-stage biotech attracts speculative growth investors betting on binary clinical outcomes. Institutional ownership likely concentrated in specialized healthcare funds. Not suitable for value or income investors given negative earnings, no dividends, and distant profitability timeline. Momentum traders active around data readout catalysts.
high - Clinical-stage biotech with binary event risk exhibits extreme volatility. Stock can move 30-50% on single trial readouts. Recent 6-month return of 61.4% followed by 1-year return of -38.7% demonstrates characteristic boom-bust pattern. Beta likely 1.5-2.0x relative to broader market.
